In Part 3 of Sacha’s conversation with Dr. Evan Nadler — one of the nation’s leading pediatric bariatric surgeons — they explore the future of obesity treatment with clarity, honesty, and real hope.
Dr. Nadler breaks down why new medications aren’t just “stronger versions” of each other, how different receptor pathways may help people who don’t respond to certain GLP-1s, and why surgery and medication together will likely shape the next era of care. He and Sacha also talk through his telemedicine weight-management program, the crisis of access in pediatric obesity treatment, and how integrated care could finally bring support to families who’ve been overlooked.
If you’ve ever wondered what’s coming next in obesity care — and what it means for real people who are doing their best with the tools they have — this episode will help connect the dots.
🧭 In This Episode
- Why “hope and science” actually work together in obesity treatment
- What new medications are targeting — and why receptor variety matters
- How early weight-loss patterns may predict long-term response
- Why surgery + medications may be the strongest approach for many patients
- The massive gap in pediatric access — and how telemedicine could change it
- The risks and realities of compounded and gray-market medications
- What a future integrated, one-stop weight-management system could look like
🪞 Key Takeaways
- New meds don’t just “work better” — they target different biological pathways that may help non-responders.
- Early weight-loss trends after surgery can signal who may need additional support.
- Some patients who don’t respond to surgery also don’t respond well to certain medications — pointing to underlying biological drivers.
- Access remains one of the biggest barriers in pediatric obesity care; many clinics literally cannot see the patients who need the most help.
- Telemedicine may become a crucial entry point for kids and families shut out by geography, waitlists, or equipment limitations.
- Compounded and gray-market medications come with risks — but patients often pursue them out of necessity, not preference.
- The future of care may include integrated meal planning, wearables, coaching, exercise, and medical oversight in one single hub.
⚠️ Content Note
Includes discussion of obesity treatment, pediatric care, access barriers, medication sourcing (compounded/gray-market), and surgical outcomes.
Connect:
Where to find Evan:
✨ Connect with Life in the Bari Lane
🏷 Keywords / Tags
Dr. Evan Nadler, pediatric obesity, childhood obesity, bariatric surgery, GLP-1, semaglutide, tirzepatide, retatrutide, obesity treatment, weight loss medications, telemedicine, access to care, compounded meds, obesity explained, bariatric science, hypothalamic set point, metabolic health
Next Time
🎧 Next up, I’m sitting down with Jessica Setnick, one of the most respected eating disorder and food-behavior experts in the country. We’re diving into why so many of us have complicated relationships with food even after bariatric surgery, how trauma shapes eating patterns, and why “willpower” has nothing to do with it.
Jessica breaks things down in a way that feels validating, eye-opening, and honestly… freeing. You’re absolutely going to walk away with language for things you’ve felt for years.
That three-part conversation starts Wednesday — don’t miss it.
👉 Make sure you’re subscribed to Life in the Bari Lane so you don’t miss our next ride.
